We are excited to announce our participation in the San Antonio Breast Cancer Symposium® (SABCS), happening December 10-13, 2024 in San Antonio, TX.
Drop by booth #951 to explore how Haystack MRD™ provides ultrasensitive detection of residual disease and cancer recurrence. Whether you’re a clinician, researcher, or pharmaceutical innovator, let’s connect to discuss how we can collaborate to improve outcomes in breast cancer care.
This is your opportunity to learn how Haystack MRD is advancing precision oncology. See you in San Antonio!
About Haystack MRD
Next-generation ctDNA detection with exquisite sensitivity and specificity for precise MRD reporting
Haystack MRD is a tumor-informed blood-based ctDNA detection test for postsurgical measurement of residual disease in solid tumor settings. Exquisite sensitivity and specificity translate to better MRD detection for greater confidence when making key clinical decisions.
Purpose-built MRD technology developed by pioneers of cancer research
Haystack MRD was designed specifically for ultrasensitive ctDNA detection when testing for residual or recurrent disease. Better sensitivity means that patients are more likely to receive the right treatment at the right time, which can significantly improve outcomes and quality of life for patients who have been diagnosed with cancer.
Experience the power of Quest Diagnostics
Haystack MRD leverages the credentialed staff, labs, logistics, service, reporting, and technology of Quest Diagnostics for a streamlined testing experience. Plus, from early detection screening to diagnosis, monitoring, and beyond, Quest offers routine to advanced testing for every stage of cancer. Experience the efficiency of working with a single lab to improve the quality and speed of cancer care.
